Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Olson, Timothy C ^a   Bongartz, Tim ^a   Crowson, Cynthia S ^a   Roberts, Glenn D ^a   Orenstein, Robert ^a   Matteson, Eric L ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Histoplasmosis; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AMPHOTERICIN; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; ETANERCEPT; FLUCONAZOLE; HYDROXYCHLOROQUINE; INFLIXIMAB; ITRACONAZOLE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR; VORICONAZOLE; ANTIRHEUMATIC AGENT; CORTICOSTEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; HISTOPLASMOSIS; HUMAN; MALE; MEDICAL RECORD; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; UNITED STATES; DRUG ANTAGONISM; ELECTRONIC MEDICAL RECORD; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ELECTRONIC HEALTH RECORDS; ENDEMIC DISEASES; FEMALE; HISTOPLASMOSIS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79956194872     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-145     Document Type: Article

References (19)

1. Sathapatayavongs B, Batteiger BE, Wheat J, Slama TG, Wass JL. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983, 62(5):263-70.
2. Deepe GS. Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis 2005, 41(Suppl 3):S204-7.
3. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007, 20(1):115-32. 10.1128/CMR.00027-06, 1797635, 17223625.
4. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38(9):1261-5. 10.1086/383317, 15127338.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criterial for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-24. 10.1002/art.1780310302, 3358796.
6. Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 1986, 314(2):83-8. 10.1056/NEJM198601093140205, 3941695.
7. Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat JL. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis 2010, 50(1):85-92. 10.1086/648724, 19951231.
8. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008, 83(2):181-94. 10.4065/83.2.181, 18241628.
9. Assi MA, Sandid MS, Baddour LM, Roberts GD, Walker RC. Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients. Medicine (Baltimore) 2007, 86(3):162-9.
10. Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, Wheat LJ, Twigg HL. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003, 167(9):1279-82. 10.1164/rccm.200206-563OC, 12615627.
11. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-85. 10.1001/jama.295.19.2275, 16705109.
12. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005, 25(9):1181-92. 10.1592/phco.2005.25.9.1181, 16164393.
13. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN, Braun MM. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002, 46(10):2565-70. 10.1002/art.10583, 12384912.
14. FDA Information for Healthcare Professionals: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). FDA ALERT 2008, FDA., http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124185.htm
15. Jain VV, Evans T, Peterson MW. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med 2006, 100(7):1291-3. 10.1016/j.rmed.2005.09.020, 16545951.
16. Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis 2002, 4(3):148-51. 10.1034/j.1399-3062.2002.01016.x, 12421460.
17. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA, . Infectious Diseases Society of America Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45(7):807-25. 10.1086/521259, 17806045, Infectious Diseases Society of America.
18. Wheat J, Sarosi G, McKinsey D, Hamill R, Bradsher R, Johnson P, Loyd J, Kauffman C. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis 2000, 30(4):688-95. 10.1086/313752, 10770731.
19. Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA, Powderly W. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16(2):100-7. 10.1097/00042560-199710010-00005, 9358104.